Showing 1672 results
-
Ad hoc release /Der Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD): Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44%…
-
Press release /Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4…
-
Story /Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.
-
Story /The disease hobbles families and economies.
-
Story /Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).
-
Story /Christine Hà lost her vision at a young age – and went on to become an award-winning chef.
-
Story /Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
-
Press release /Conference call and webcast on February 27 at 4:30 p.m. EST CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments…